Our model
Patient oriented - Faster time to market - Lowered risk - Exceptional ROI
Our model embraces strategic partnerships including CRO-, data science-, software-, and DRPx companies. DRPx innovators uncover opportunity for repurposing known molecular entities for new indications. With known molecular entities this typically means that the preclinical development is accomplished, and that the safety profile is well documented. New drugs in this category can come to market with shorter lead time, at lower risk, and lower cost. This means that new therapies in pediatrics and rare conditions could become economically viable to develop. With outsourced partnerships in clinical research, OrchestratePharma is able to stay agile and scale with optimized working capital.
We are particularly interested in strategic partnerships which have the potential to accelerate paths to market leveraging existing data sources. Recognizing both the importance of prevention and behavioral change as part of therapies, we are interested in partnerships that have the potential to deliver incremental patient value.
Collaboration
OrchestratePharma embraces win-win models of collaboration with its partners. We drive alignment of objectives and pairing of capabilities, which together can drive successful outcomes. We enter into success-based sharing models for aligned incentives.
Repurposing for speed & efficiency
- DRPx can reduce the drug development cost to 1/20. Where de novo drug development can cost more than $1bn, the same cost for DRPx can be less than $50m.
- DRPx can reduce the time to market to 5 years compared with in average 14 years for de novo drug development.
- The risk rate for DRPx is generally only 3:10 whilst being as high as 1:100000 in de novo drug development.
(Ref: Global Data Healthcare).
Holistic solutions
We are particularly interested in strategic partnerships which have the potential to improve effectiveness of therapies and those which can accelerate paths to market. We extensively re-use our internally generated data and look to leverage other external data sources. We recognize the importance of behavioral change in effectivity of therapies and look to partnerships or co-creation opportunities that can collectively drive such patient value.
